Published in J Virol on November 14, 2016
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet (2000) 6.12
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med (1984) 5.47
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science (2009) 3.69
Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol (2007) 3.58
HIV-infected T cells are migratory vehicles for viral dissemination. Nature (2012) 3.57
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med (1999) 3.11
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Virus entry, assembly, budding, and membrane rafts. Microbiol Mol Biol Rev (2003) 2.68
Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses (2001) 2.60
Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol (2002) 2.49
Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. J Virol (2009) 2.33
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol (2008) 2.27
Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol (2010) 2.12
Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog (2012) 1.74
Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. Science (2015) 1.65
Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol (2004) 1.61
Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol (2009) 1.61
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol (1998) 1.51
Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine (2009) 1.32
Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med (2013) 1.28
Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol (2008) 1.28
Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS (2009) 1.26
A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J Biol Chem (2006) 1.23
Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med (2012) 1.23
Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J Immunol (2007) 1.21
CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One (2014) 1.16
HIV entry in macrophages is dependent on intact lipid rafts. Virology (2009) 1.15
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol (2011) 1.05
Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail. J Virol (2012) 1.01
Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. J Infect Dis (2012) 0.98
GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology (2010) 0.97
Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine (2013) 0.96
Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol (2012) 0.93
Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. AIDS Res Hum Retroviruses (2011) 0.91
Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes. Blood (2012) 0.89
Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans. J Virol (2008) 0.89
Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. PLoS Pathog (2015) 0.85
Molecular basis of genetic polymorphism in major histocompatibility complex-linked proteasome gene (Lmp-2). Proc Natl Acad Sci U S A (1993) 0.84
Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J Virol (2011) 0.82
Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J Virol (2012) 0.81
Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. J Virol (2013) 0.80
Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus immunoglobulin Fab domains in Escherichia coli. Hybridoma (1995) 0.76
Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J Virol (2012) 0.81
Glycosyl-phosphatidylinositol (GPI)-anchored anti-HIV scFv efficiently protect CD4 T cells from HIV-1 infection and deletion in hu-PBL mice. J Virol (2016) 0.75